tetano
Editor, Senior Moderator
Mol Genet Metab
. 2023 May 11;139(2):107607.
doi: 10.1016/j.ymgme.2023.107607. Online ahead of print. COVID-19 in inherited metabolic disorders: Clinical features and risk factors for disease severity
Ayca Burcu Kahraman[SUP] 1 [/SUP], Yılmaz Yıldız[SUP] 2 [/SUP], Kısmet Çıkı[SUP] 3 [/SUP], Izzet Erdal[SUP] 4 [/SUP], Halil Tuna Akar[SUP] 5 [/SUP], Ali Dursun[SUP] 6 [/SUP], Ayşegül Tokatlı[SUP] 7 [/SUP], Serap Sivri[SUP] 8 [/SUP]
Affiliations
Background: Old age, obesity, and certain chronic conditions are among the risk factors for severe COVID-19. More information is needed on whether inherited metabolic disorders (IMD) confer risk of more severe COVID-19. We aimed to establish COVID-19 severity and associated risk factors in patients with IMD currently followed at a single metabolic center.
Methods: Among all IMD patients followed at a single metabolic referral center who had at least one clinic visit since 2018, those with accessible medical records were reviewed for SARS-CoV-2 tests. COVID-19 severity was classified according to the WHO recommendations, and IMD as per the international classification of IMD.
Results: Among the 1841 patients with IMD, 248 (13.5%) had tested positive for COVID-19, 223 of whom gave consent for inclusion in the study (131 children and 92 adults). Phenylalanine hydroxylase (48.4%) and biotinidase (12.1%) deficiencies were the most common diagnoses, followed by mucopolysaccharidoses (7.2%). 38.1% had comorbidities, such as neurologic disabilities (22%) or obesity (9.4%). The majority of COVID-19 episodes were asymptomatic (16.1%) or mild (77.6%), but 6 patients (2.7%) each had moderate and severe COVID-19, and two (0.9%) had critical COVID-19, both of whom died. 3 patients had an acute metabolic decompensation during the infection. Two children developed multisystem inflammatory syndrome (MIS-C). Long COVID symptoms were present in 25.2%. Presence of comorbidities was significantly associated with more severe COVID-19 in adults with IMD (p < 0.01), but not in children (p = 0.45). Compared to other categories of IMD, complex molecule degradation disorders were significantly associated with more severe COVID-19 in children (p < 0.01); such a significant IMD category distinction was not found in adults.
Discussion: This is the largest study on COVID-19 in IMD patients relying on real-word data and objective definitions, and not on merely expert opinions or physician surveys. COVID-19 severity and long COVID incidence in IMD are probably similar to the general population, and the risk of acute metabolic decompensation is not likely to be greater than that in other acute infections. Disease category (complex molecule degradation) in children, and comorbidities in adults may be associated with COVID-19 severity in IMD. Additionally, the first documented accounts of COVID-19 in 27 different IMD are recorded. The high occurrence of MIS-C may be coincidental, but warrants further study.
Keywords: Comorbidity; Coronavirus disease 2019 (COVID-19); Disorders of complex molecule degradation; Inherited metabolic diseases; Pneumonia; SARS-CoV-2.
. 2023 May 11;139(2):107607.
doi: 10.1016/j.ymgme.2023.107607. Online ahead of print. COVID-19 in inherited metabolic disorders: Clinical features and risk factors for disease severity
Ayca Burcu Kahraman[SUP] 1 [/SUP], Yılmaz Yıldız[SUP] 2 [/SUP], Kısmet Çıkı[SUP] 3 [/SUP], Izzet Erdal[SUP] 4 [/SUP], Halil Tuna Akar[SUP] 5 [/SUP], Ali Dursun[SUP] 6 [/SUP], Ayşegül Tokatlı[SUP] 7 [/SUP], Serap Sivri[SUP] 8 [/SUP]
Affiliations
- PMID: 37201420
- DOI: 10.1016/j.ymgme.2023.107607
Background: Old age, obesity, and certain chronic conditions are among the risk factors for severe COVID-19. More information is needed on whether inherited metabolic disorders (IMD) confer risk of more severe COVID-19. We aimed to establish COVID-19 severity and associated risk factors in patients with IMD currently followed at a single metabolic center.
Methods: Among all IMD patients followed at a single metabolic referral center who had at least one clinic visit since 2018, those with accessible medical records were reviewed for SARS-CoV-2 tests. COVID-19 severity was classified according to the WHO recommendations, and IMD as per the international classification of IMD.
Results: Among the 1841 patients with IMD, 248 (13.5%) had tested positive for COVID-19, 223 of whom gave consent for inclusion in the study (131 children and 92 adults). Phenylalanine hydroxylase (48.4%) and biotinidase (12.1%) deficiencies were the most common diagnoses, followed by mucopolysaccharidoses (7.2%). 38.1% had comorbidities, such as neurologic disabilities (22%) or obesity (9.4%). The majority of COVID-19 episodes were asymptomatic (16.1%) or mild (77.6%), but 6 patients (2.7%) each had moderate and severe COVID-19, and two (0.9%) had critical COVID-19, both of whom died. 3 patients had an acute metabolic decompensation during the infection. Two children developed multisystem inflammatory syndrome (MIS-C). Long COVID symptoms were present in 25.2%. Presence of comorbidities was significantly associated with more severe COVID-19 in adults with IMD (p < 0.01), but not in children (p = 0.45). Compared to other categories of IMD, complex molecule degradation disorders were significantly associated with more severe COVID-19 in children (p < 0.01); such a significant IMD category distinction was not found in adults.
Discussion: This is the largest study on COVID-19 in IMD patients relying on real-word data and objective definitions, and not on merely expert opinions or physician surveys. COVID-19 severity and long COVID incidence in IMD are probably similar to the general population, and the risk of acute metabolic decompensation is not likely to be greater than that in other acute infections. Disease category (complex molecule degradation) in children, and comorbidities in adults may be associated with COVID-19 severity in IMD. Additionally, the first documented accounts of COVID-19 in 27 different IMD are recorded. The high occurrence of MIS-C may be coincidental, but warrants further study.
Keywords: Comorbidity; Coronavirus disease 2019 (COVID-19); Disorders of complex molecule degradation; Inherited metabolic diseases; Pneumonia; SARS-CoV-2.